逍遥散联合恩替卡韦治疗肝郁脾虚型慢性乙型肝炎疗效研究

目的:探究逍遥散联合恩替卡韦治疗肝郁脾虚型慢性乙型肝炎(CHB)的临床疗效。方法:选取慢性乙型肝炎患者100例,用随机数字表法将患者分为观察组和对照组,每组各50例。对照组给予恩替卡韦治疗,观察组给予恩替卡韦加逍遥散,比较两组患者的中医证候、血清病毒载量、肝脏硬度及不良反应等相关指标。结果:治疗3个月后,观察组的各项中医证候评分均低于对照组(P<0.05),临床疗效总有效率为92.00%高于对照组的76.00%(P<0.05)。治疗3个月后HBV-DNA转阴率观察组仍高于对照组,FS值小于对照组(P<0.05)。治疗6个月后,观察组的HBV-DNA转阴率高于对照组(P<0.05),FS值小于对照组(P<0.05)。两组患者均未出现严重的不良反应,总不良反应发生率比较,无统计学差异(P>0.05)。结论:逍遥散联合恩替卡韦治疗,能有效改善肝郁脾虚型CHB患者的临床证候,促进HBV-DNA阴转,降低肝脏硬度,且不良反应较少。

Study on effect of Xiaoyao powder combined with entecavir on patients with chronic hepatitis B of Ganyu Pixu type

Objective:To explore clinical curative effect of Xiaoyao powder combined with entecavir on chronic hepatitis B(CHB)of Ganyu Pixu type.Methods:Total of 100 CHB patients were divided into observation group and control group by random number table method,50 cases in each group.The control group were treated with entecavir,while observation group were treated with entecavir and Xiaoyao powder.TCM symptoms,serum viral load,liver stiffness and adverse reactions were compared between the two groups.Results:After 3 months of treatment,scores of all TCM syndromes in the observation group were lower than those in the control group(P<0.05),while total response rate of clinical curative effect was higher than that in the control group(92.00% vs 76.00%)(P<0.05).After 3 months of treatment,negative conversion ratio of HBV-DNA in the observation group was higher than that in the control group(P>0.05),while FS value was less than that in the control group(P<0.05).After 6 months of treatment,negative conversion ratio of HBV-DNA in the observation group was higher than that in control group(P<0.05),and the FS value was smaller than that of the control group(P<0.05).There were no serious adverse reactions in either group.There was no significant difference in total incidence of adverse reactions between the two groups(P>0.05).Conclusion: Xiaoyao powder combined with entecavir can effectively improve clinical symptoms of CHB patients of Ganyu Pixu type,promote negative conversion of HBV-DNA,reduce liver stiffness,with few adverse reactions.Its clinical curative effect is better than that of entecavir alone.